Conclusion
This review article summarizes current gene therapy strategies for the
treatment of atrial fibrillation. Further development of gene therapy
for this condition is encouraged by the limited efficacy of
pharmacological and catheter-based therapies for AF. While AF remains a
complex and heterogeneous clinical entity, gene therapy targeting
multiple signaling pathways show very promising results in pre-clinical
models. Improved longevity of vectors and expansion of targeting and
delivery of vectors may lead to the development of effective and
long-lasting treatment for AF.